Nephros Inc Stock Price, News & Analysis

Nephros, Inc. (Nasdaq: NEPH) announced that CEO Andy Astor will present at the 2022 Virtual Growth Conference. The event occurs from March 28th to 30th, starting at 9:00 AM ET on March 28th. Astor's presentation will focus on Nephros's innovations in water safety through pathogen detection and purification solutions for healthcare and commercial markets. The conference, hosted by Maxim Group LLC and M-Vest, features discussions across various sectors including healthcare, clean energy, and technology.

Nephros reported a full-year net revenue of $10.4 million for 2021, reflecting a 22% year-over-year increase. The fourth quarter net revenue reached $2.8 million, up 18% from 2020. For 2022, the company reaffirmed its guidance of $13.0 million to $13.5 million, expecting a growth rate of 25% to 30%. However, the company incurred a net loss of $3.9 million for the year, though this is a 15% improvement from the previous year. The operating loss for the fourth quarter was ($1.0 million), a 37% increase year-over-year. Nephros had approximately $7.0 million in cash as of year-end.

Nephros, a water technology company, announced its plan to release fourth quarter financial results on February 23, 2022. The results will be disclosed after market close, followed by a conference call at 4:30 PM ET. Participants can access the call through domestic and international phone lines. A replay will be available until March 2, 2022. Nephros specializes in innovative filtration and pathogen detection solutions for the healthcare and commercial sectors, emphasizing a commitment to water safety.

RION, a biotechnology company based in Rochester, Minnesota, has appointed Alisa Lask as Chief Commercial Officer. Lask brings extensive experience from leadership roles at major firms including Galderma and Allergan, aiming to commercially leverage RION's groundbreaking exosome therapeutics. The company currently has two active FDA registrations and focuses on innovative biologic platforms for regenerative medicine. Dr. Atta Behfar, RION's founder, expressed confidence in Lask's strategic vision to drive growth in both therapeutic and aesthetic sectors.

Nephros, Inc. (Nasdaq: NEPH) has announced a strong start to 2022, expecting revenue between $13-13.5 million, a projected increase of 25-30% from 2021's $10.4 million. The company attributes its growth to a revamped marketing strategy and new water management standards from CMS. Nephros has seen a 35% increase in facilities using its filters over the past two years and is focused on expanding its pathogen detection systems. The FDA is reviewing its HDF Assist Device, with a commercial launch anticipated in late 2022.

Nephros, Inc. (Nasdaq: NEPH) has announced record preliminary net revenue of $10.4 million for fiscal year 2021, marking a 21% increase year-over-year. The fourth quarter also showed strong performance with $2.8 million in revenue, an 18% year-over-year increase. Looking ahead, the company projects 2022 revenue guidance between $13.0 million and $13.5 million, indicating 25-30% growth. With approximately $7 million in cash, Nephros is well-positioned for growth. Full results will be detailed on February 23, 2022.

Nephros, Inc. (Nasdaq: NEPH), a water technology company, announced that CEO Andy Astor will attend the Benchmark Company's 10th Annual One-on-One Discovery Conference on December 2, 2021. This virtual event is invitation-only and designed for institutional clients. Nephros specializes in filtration and pathogen detection solutions for healthcare and commercial markets, aiming to enhance water safety and management.

Nephros, Inc. (NASDAQ: NEPH) reported Q3 2021 financial results with net revenue of $2.6 million, a 24% increase year-over-year. Despite revenue growth, net loss rose to $1.2 million, up 15%. Adjusted EBITDA improved by 22% to ($0.7 million). The company highlighted that year-to-date revenue reached a record high, driven by growth in the water filtration segment, despite challenges from the COVID-19 Delta variant. The FDA is reviewing Nephros’s second-generation HDF system, with expectations for growth in their pathogen detection segment in 2022.

Nephros, a leader in water technology, will release its third quarter financial results on November 4, 2021, post-market. A conference call will be held at 4:30 PM ET on the same day for discussion. Domestic participants can dial 1-844-808-7106, while international callers can reach 1-412-317-5285. A replay of the call will be available until November 11, 2021. Nephros is dedicated to enhancing water safety through its innovative filtration and pathogen detection solutions, serving healthcare and commercial markets.